These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15752919)

  • 1. Management of diabetic dyslipidemia.
    Del Pilar Solano M; Goldberg RB
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):1-25, v. PubMed ID: 15752919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?
    Kendall DM
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):27-48. PubMed ID: 15752920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials and lipid guidelines for type II diabetes.
    Prisant LM
    J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipidemia in children with type 2 diabetes mellitus.
    Taha D
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():505-7. PubMed ID: 12017224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia in type 2 diabetes.
    Krauss RM; Siri PW
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
    Goldberg RB
    Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.